Distinct von Hippel-Lindau gene and hypoxia-regulated alterations in gene and protein expression patterns of renal cell carcinoma and their effects on metabolism

During the last decade the knowledge about the molecular mechanisms of the cellular adaption to hypoxia and the function of the “von Hippel Lindau” (VHL) protein in renal cell carcinoma (RCC) has increased, but there exists little information about the overlap and differences in gene/protein expression of both processes. Therefore the aim of this study was to dissect VHL- and hypoxia-regulated alterations in the metabolism of human RCC using ome-based strategies. The effect of the VHL- and hypoxia-regulated altered gene/protein expression pattern on the cellular metabolism was analyzed by determination of glucose uptake, lactate secretion, extracellular pH, lactate dehydrogenase activity, amino acid content and ATP levels. By employing VHL−/VHL+ RCC cells cultured under normoxic and hypoxic conditions, VHL-dependent, HIF-dependent as well as VHL-/HIF-independent alterations in the gene and protein expression patterns were identified and further validated in other RCC cell lines. The genes/proteins differentially expressed under these distinct conditions were mainly involved in the cellular metabolism, which was accompanied by an altered metabolism as well as changes in the abundance of amino acids in VHL-deficient cells. In conclusion, the study reveals similarities, but also differences in the genes and proteins controlled by VHL functionality and hypoxia thereby demonstrating differences in the metabolic switch of RCC under these conditions.

[1]  Z. Husain,et al.  Tumor-Derived Lactate Modifies Antitumor Immune Response: Effect on Myeloid-Derived Suppressor Cells and NK Cells , 2013, The Journal of Immunology.

[2]  G. Stephanopoulos,et al.  In vivo HIF-mediated reductive carboxylation is regulated by citrate levels and sensitizes VHL-deficient cells to glutamine deprivation. , 2013, Cell metabolism.

[3]  P. Oefner,et al.  Delaying aging and the aging-associated decline in protein homeostasis by inhibition of tryptophan degradation , 2012, Proceedings of the National Academy of Sciences.

[4]  Bin Hu,et al.  Tumor lactic acidosis suppresses CTL function by inhibition of p38 and JNK/c‐Jun activation , 2012, International journal of cancer.

[5]  A. Mackensen,et al.  Tumor metabolism as modulator of immune response and tumor progression. , 2012, Seminars in cancer biology.

[6]  B. Seliger,et al.  HER-2/neu-mediated Down-regulation of Biglycan Associated with Altered Growth Properties* , 2012, The Journal of Biological Chemistry.

[7]  B. Seliger,et al.  Warburg phenotype in renal cell carcinoma: High expression of glucose‐transporter 1 (GLUT‐1) correlates with low CD8+ T‐cell infiltration in the tumor , 2011, International journal of cancer.

[8]  B. Seliger,et al.  Systematic Comparative Protein Expression Profiling of Clear Cell Renal Cell Carcinoma , 2009, Molecular & Cellular Proteomics.

[9]  B. Rini,et al.  Renal cell carcinoma , 2009, The Lancet.

[10]  G. Semenza,et al.  Uterine DCs are essential for pregnancy. , 2008, The Journal of clinical investigation.

[11]  W. Kaelin The von Hippel–Lindau tumour suppressor protein: O2 sensing and cancer , 2008, Nature Reviews Cancer.

[12]  C. Charbonneau,et al.  Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. , 2008, Cancer treatment reviews.

[13]  B. Seliger,et al.  Aminopeptidase N (APN)/CD13-dependent CXCR4 downregulation is associated with diminished cell migration, proliferation and invasion , 2008, Molecular membrane biology.

[14]  C. Thompson,et al.  HIF and c-Myc: sibling rivals for control of cancer cell metabolism and proliferation. , 2007, Cancer cell.

[15]  Gregor Rothe,et al.  Inhibitory effect of tumor cell-derived lactic acid on human T cells. , 2007, Blood.

[16]  B. Seliger,et al.  Influence of Ki‐ras‐driven oncogenic transformation on the protein network of murine fibroblasts , 2007, Proteomics.

[17]  Max Costa,et al.  Hypoxia-Inducible Factor-1 (HIF-1) , 2006, Molecular Pharmacology.

[18]  P. Selby,et al.  Proteomic identification of a role for the von Hippel Lindau tumour suppressor in changes in the expression of mitochondrial proteins and septin 2 in renal cell carcinoma , 2006, Proteomics.

[19]  V. Haase,et al.  The VHL/HIF oxygen-sensing pathway and its relevance to kidney disease. , 2006, Kidney international.

[20]  A. Mackensen,et al.  Tumor-derived lactic acid modulates dendritic cell activation and antigen expression. , 2006, Blood.

[21]  G. Semenza,et al.  Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1. , 2005, Blood.

[22]  G. Semenza Targeting HIF-1 for cancer therapy , 2003, Nature Reviews Cancer.

[23]  M. Knowles,et al.  Proteomic changes in renal cancer and co‐ordinate demonstration of both the glycolytic and mitochondrial aspects of the Warburg effect , 2003, Proteomics.

[24]  B. Seliger,et al.  Identification of metabolic enzymes in renal cell carcinoma utilizing PROTEOMEX analyses. , 2003, Biochimica et biophysica acta.

[25]  U. K. Laemmli,et al.  Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 , 1970, Nature.

[26]  M. Takashi,et al.  Elevated levels of serum aldolase A in patients with renal cell carcinoma , 2004, Urological Research.